扩散加权MRI作为头颈癌肿瘤反应与肿瘤学结局生物标志物的前瞻性验证:一项观察性生物标志物预认证研究结果
这项前瞻性观察性生物标志物预认证研究纳入81例接受放疗的头颈癌患者,于放疗前、中、后行MRI并提取表观扩散系数(ADC)。放疗后达完全缓解(CR)者放疗中期平均ADC较基线显著升高,未达CR者无显著升高;放疗中期GTV-P ΔADCmean≥7%与更好的局部控制(LC)和无复发生存(RFS)显著相关,且较标准临床变量显著改善LC和RFS模型的c指数。
要点
- 放疗中期原发肿瘤ADC无显著升高者疾病复发风险高。
- 放疗中期GTV-P ΔADCmean≥7%与更好的LC和RFS显著相关。
- ΔADCmean较标准临床变量显著改善LC和RFS模型的c指数。
核心结论
- 放疗中期ΔADCmean是头颈癌肿瘤学结局的强预测因子。
- 放疗中期原发肿瘤ADC无显著升高者疾病复发风险高。
研究设计与样本
- 前瞻性观察性生物标志物预认证研究,纳入81例接受放疗的头颈癌患者。
- 患者于放疗前、放疗中期和放疗完成后行MRI,以T2加权序列勾画肿瘤并配准至相应DWI提取ADC测量值。
- 放疗中期和放疗后评估治疗反应,分为完全缓解(CR)与非完全缓解(non-CR)。
主要发现
- 中位随访31个月。
- 放疗后达CR者放疗中期平均ADC较基线显著升高((1.8 ± 0.29) × 10-3 mm2/s vs. (1.37 ± 0.22) × 10-3 mm2/s,p < 0.0001),non-CR者无显著升高(p > 0.05)。
- 递归分割分析(RPA)识别出放疗中期GTV-P ΔADCmean < 7%是与更差LC和RFS相关的最显著参数(p = 0.01)。
- 单因素和多因素分析显示放疗中期GTV-P ΔADCmean ≥ 7%与更好的LC和RFS显著相关。
- 加入ΔADCmean较标准临床变量显著改善LC和RFS模型的c指数(LC:0.85 vs. 0.77;RFS:0.74 vs. 0.68;两者p < 0.0001)。
关键数值与推荐
- 放疗后达CR者放疗中期平均ADC为(1.8 ± 0.29) × 10-3 mm2/s,基线为(1.37 ± 0.22) × 10-3 mm2/s,p < 0.0001。
- RPA识别放疗中期GTV-P ΔADCmean < 7%与更差LC和RFS相关(p = 0.01)。
- 放疗中期GTV-P ΔADCmean ≥ 7%与更好的LC和RFS显著相关。
- LC模型c指数0.85 vs. 0.77,RFS模型c指数0.74 vs. 0.68,两者p < 0.0001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine DWI parameters associated with tumor response and oncologic outcomes in head and neck (HNC) patients treated with radiotherapy (RT). METHODS: HNC patients in a prospective study were included. Patients had MRIs pre-, mid-, and post-RT completion. We used T2-weighted sequences for tumor segmentation which were co-registered to respective DWIs for extraction of apparent diffusion coefficient (ADC) measurements. Treatment response was assessed at mid- and post-RT and was defined as: complete response (CR) vs. non-complete response (non-CR). The Mann-Whitney U test was used to compare ADC between CR and non-CR. Recursive partitioning analysis (RPA) was performed to identify ADC threshold associated with relapse. Cox proportional hazards models were done for clinical vs. clinical and imaging parameters and internal validation was done using bootstrapping technique. RESULTS: Eighty-one patients were included. Median follow-up was 31 months. For patients with post-RT CR, there was a significant increase in mean ADC at mid-RT compared to baseline ((1.8 ± 0.29) × 10-3 mm2/s vs. (1.37 ± 0.22) × 10-3 mm2/s, p < 0.0001), while patients with non-CR had no significant increase (p > 0.05). RPA identified GTV-P delta (Δ)ADCmean < 7% at mid-RT as the most significant parameter associated with worse LC and RFS (p = 0.01). Uni- and multi-variable analysis showed that GTV-P ΔADCmean at mid-RT ≥ 7% was significantly associated with better LC and RFS. The addition of ΔADCmean significantly improved the c-indices of LC and RFS models compared with standard clinical variables (0.85 vs. 0.77 and 0.74 vs. 0.68 for LC and RFS, respectively, p < 0.0001 for both). CONCLUSION: ΔADCmean at mid-RT is a strong predictor of oncologic outcomes in HNC. Patients with no significant increase of primary tumor ADC at mid-RT are at high risk of disease relapse.
引用
- Mohamed ASR, Abusaif A, He R, et al. Prospective validation of diffusion-weighted MRI as a biomarker of tumor response and oncologic outcomes in head and neck cancer: Results from an observational biomarker pre-qualification study. Radiother Oncol. 2023. PMID: 36990394. doi:10.1016/j.radonc.2023.109641
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。